Neuroendocrine prostate cancer: Subtypes, biology, and clinical outcomes

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 5, 2014, Pages 719-726

  Aggarwal, Rahul ^a   Zhang, Tian ^b   Small, Eric J ^a   Armstrong, Andrew J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AURORA A KINASE; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL FEATURE; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; METASTASIS; NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; NOMENCLATURE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SMALL CELL CARCINOMA; CARCINOMA; FEMALE; MALE; PROSTATE TUMOR;

CARCINOMA, NEUROENDOCRINE; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84900463472     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0073     Document Type: Review

References (34)

1. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621-3630.
2. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-3080. (Pubitemid 34791096)
3. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000;31:406-414. (Pubitemid 30262860)
4. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-687. (Pubitemid 26240320)
5. Berruti A, Bollito E, Cracco CM, et al. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate 2010;70:718-726.
6. Hirano D, Okada Y, Minei S, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-592. (Pubitemid 38481685)
7. Flechon A, Pouessel D, Ferlay C, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22:2476-2481.
8. Evans AJ, Humphrey PA, Belani J, et al. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30:684-693. (Pubitemid 44264993)
9. Adlakha H, Bostwick DG. Paneth cell-like change in prostate adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol 1994;25:135-139. (Pubitemid 24079632)
10. Almagro UA. Argyrophilic prostatic carcinoma: case report with literature review on prostatic carcinoid and "carcinoid-like" prostatic carcinoma. Cancer 1985;55:608-614. (Pubitemid 15156031)
11. Beltran H, Mosquera JM, Rubin MA. Neuroendocrine prostate cancer. In: Tewari A, ed. Prostate Cancer: A Comprehensive Perspective. London, England: Springer-Verlag; 2013.
12. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820-828.
13. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.
14. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705-712. (Pubitemid 44264995)
15. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147:804-807.
16. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005;47:1-16. (Pubitemid 40978808)
17. Furtado P, Lima MV, Nogueira C, et al. Review of small cell carcinomas of the prostate. Prostate Cancer 2011;2011:543272.
18. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109-117. (Pubitemid 40477092)
19. Isshiki S, Akakura K, Komiya A, et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-515. (Pubitemid 34074517)
20. Marcus DM, Goodman M, Jani AB, et al. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 2012;15:283-288.
21. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531-547. (Pubitemid 350074046)
22. Ather MH, Abbas F, Faruqui N, et al. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 2008;8:21.
23. Lapuk AV, Wu C, Wyatt AW, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012;227:286-297.
24. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487-495.
25. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 2007;282:3571-3583. (Pubitemid 47084471)
26. Ciarlo M, Benelli R, Barbieri O, et al. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. Int J Cancer 2012;131:582-590.
27. Pagliarini R. ERG influences cell fate decisions in prostate cancer. Presenteed at the 20th Annual Prostate Cancer Foundation Scientific Retreat; October 23-26, 2013; National Harbor, Maryland.
28. Frigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 2008;7:659-669. (Pubitemid 351482148)
29. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
30. Aparicio A, Tzelepi V, Araujo JC, et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011;71:846-856.
31. Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012;18:666-677.
32. Chiaverotti T, Couto SS, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-246. (Pubitemid 351186384)
33. Mohler JL, Kantoff PW, Armstrong AJ, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2014. Available at NCCN.org. Accessed January 24, 2014.
34. Kalemkerian GP, Akerley W, Bogner P, et al. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2014. Available at NCCN.org. Accessed January 24, 2014.